Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: Systematic review and meta-analyses

British Journal of Psychiatry

Volumn 213, Issue 3, 2018, Pages 514-525

  Rowland, Tobias ^a   Perry, Benjamin I ^a   Upthegrove, Rachel ^a   Barnes, Nicholas ^b   Chatterjee, Jayanta ^c   Gallacher, Daniel ^a   Marwaha, Steven ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

Author keywords

Biomarkers; bipolar disorder; cytokines, neurotrophins; meta analysis; oxidative stress; review

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LITHIUM; NEUROLEPTIC AGENT; NEUROTROPHIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; BIOLOGICAL MARKER;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL FEATURE; ELECTROCONVULSIVE THERAPY; HUMAN; META ANALYSIS; MOOD; OXIDATIVE STRESS; REVIEW; SYSTEMATIC REVIEW; AFFECT; BLOOD; METABOLISM; PSYCHOLOGY;

AFFECT; BIOMARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; OXIDATIVE STRESS;

EID: 85055106309     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.2018.144     Document Type: Review

References (117)

1. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68: 241-51.
2. Krahn GL. WHO World Report on Disability: A review. Disabil Health J 2011; 4: 141-2.
3. Saunders KE, Bilderbeck AC, Price J, Goodwin GM. Distinguishing bipolar disorder from borderline personality disorder: A study of current clinical practice. Eur Psychiatry 2015; 30: 965-74.
4. Baldessarini RJ, Tondo L, Baethge CJ, Lepri B, Bratti IM. Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disord 2007; 9: 386-93.
5. Joyce K, Thompson A, Marwaha S. Is treatment for bipolar disorder more effective earlier in illness course A comprehensive literature review. Int J Bipolar Disord 2016; 4: 19.
6. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: A systematic review and meta-analysis. J Affect Disord 2013; 144: 16-27.
7. Fernandes BS, Molendijk ML, Kohler CA, Soares JC, Leite CM, Machado-Vieira R, et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: A meta-analysis of 52 studies. BMC Med 2015; 13: 289.
8. Green EK, Raybould R, Macgregor S, Hyde S, Young AH, O'Donovan MC, et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: Case-control study of over 3000 individuals from the UK. Br J Psychiatry 2006; 188: 21-5.
9. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005; 6: 603-14.
10. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010; 7: 243-50.
11. Wu R, Fan J, Zhao J, Calabrese JR, Gao K. The relationship between neurotrophins and bipolar disorder. Expert Rev Neurother 2014; 14: 51-65.
12. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: A meta-analytic study. Neurosci Lett 2009; 466: 139-43.
13. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, SchroeterML. BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis. J Affect Disord 2015; 174: 432-40.
14. Munkholm K, Vinberg M, Kessing LV. Peripheral blood brain-derived neurotrophic factor in bipolar disorder: A comprehensive systematic review and meta-analysis. Mol Psychiatry 2016; 21: 216-28.
15. Fries GR, Pfaffenseller B, Stertz L, Paz AV, Dargel AA, Kunz M, et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep 2012; 14: 667-75.
16. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder v. healthy control subjects: A systematic review and meta-analysis. J Psychiatr Res 2013; 47: 1119-33.
17. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biol Psychiatry 2013; 74: 15-25.
18. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al. Oxidative stress markers in bipolar disorder: A meta-analysis. J Affect Disord 2008; 111: 135-44.
19. Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 2014; 218: 61-8.
20. Haenisch F, Cooper JD, Reif A, Kittel-Schneider S, Steiner J, Leweke FM, et al. Towards a blood-based diagnostic panel for bipolar disorder. Brain Behav Immun 2016; 52: 49-57.
21. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 2009; 14: 156-74.
22. Dayan CM. Interpretation of thyroid function tests. Lancet 2001; 357: 619-24.
23. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen 1998; 5: 115-9.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151: 264-9.
25. Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of google scholar in evidence reviews and its applicability to grey literature searching. PLoS one 2015; 10: E0138237.
26. Wells GA, Shea B, O'Connell D, Peterson JEA, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute, 2000.
27. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: D4002.
28. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006; 333: 597-600.
29. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatry Res 2007; 41: 523-9.
30. Asdemir A, Turan T, Uysal C, Kilic E. A potential biomarker for bipolar I disorder: Serum arginine vasopressin levels. Anatolian J Psychiatry 2017; 18: 195-202.
31. Aydemir O, Cubukcuoglu Z, Erdin S, Tas C, Onur E, Berk M. Oxidative stress markers, cognitive functions, psychosocial functioning in bipolar disorder: An empirical cross-sectional study. Rev Bras Psiquiatr 2014; 36: 293-7.
32. Bai YM, Su TP, Tsai SJ, Wen-Fei C, Li CT, Pei-Chi T, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord 2014; 166: 187-92.
33. Barbosa IG, Huguet RB, Mendonca VA, Sousa LP, Neves FS, Bauer ME, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011; 261: 139-43.
34. Barbosa IG, Morato IB, Huguet RB, Rocha FL, Machado-Vieira R, Teixeira AL. Decreased plasma neurotrophin-4/5 levels in bipolar disorder patients in mania. Rev Bras Psiquiatr 2014; 36: 340-3.
35. Barbosa IG, Rocha NP, Huguet RB, Ferreira RA, Salgado JV, Carvalho LA, et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord 2012; 137: 151-5.
36. Barbosa IG, Rocha NP, Miranda AS, Huguet RB, Bauer ME, Reis HJ, et al. Increased BDNF levels in long-term bipolar disorder patients. Rev Bras Psiquiatr 2013; 35: 67-9.
37. Cetin T, Guloksuz S, Cetin EA, Gazioglu SB, Deniz G, Oral ET, et al. Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry 2012; 12: 158.
38. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398: 215-9.
39. de Oliveira GS, Cereser KM, Fernandes BS, Kauer-Sant'Anna M, Fries GR, Stertz L, et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 2009; 43: 1171-4.
40. Dell'Osso L, Bianchi C, Del Debbio A, Roncaglia I, Veltri A, Carlini M, et al. Plasma brain-derived neurotrophic factor in bipolar and unipolar depression. Off J Italian Soc Psychopathol 2010; 16: 138-43.
41. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 2009; 11: 663-71.
42. do Prado CH, Rizzo LB, Wieck A, Lopes RP, Teixeira AL, Grassi-Oliveira R, et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology 2013; 38: 667-76.
43. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immunity 2011; 25: 1206-13.
44. Fernandes BS, Gama CS, Kauer-Sant'Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis. J Psychiatr Res 2009; 43: 1200-4.
45. Fiedorowicz JG, Prossin AR, Johnson CP, Christensen GE, Magnotta VA, Wemmie JA. Peripheral inflammation during abnormal mood states in bipolar I disorder. J Affect Disord 2015; 187: 172-8.
46. Gergerlioglu HS, Savas HA, Bulbul F, Selek S, Uz E, Yumru M. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 697-702.
47. Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord 2010; 126: 458-62.
48. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011; 45: 1608-16.
49. Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 370-2.
50. Jacoby AS, Munkholm K, Vinberg M, Pedersen BK, Kessing LV. Cytokines, brainderived neurotrophic factor and C-reactive protein in bipolar I disorder-results from a prospective study. J Affect Disord 2016; 197: 167-74.
51. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011; 45: 156-61.
52. Karamustafalioglu N, Genc A, Kalelioglu T, Tasdemir A, Umut G, Incir S, et al. Plasma BDNFs level initially and post treatment in acute mania: Comparison between ECT and atypical antipsychotic treatment and healthy controls. J Psychopharmacol 2015; 29: 898-902.
53. Kenna HA, Reynolds-May M, Stepanenko A, Ketter TA, Hallmayer J, Rasgon NL. Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women. J Affect Disord 2014; 156: 214-8.
54. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104: 91-5.
55. Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, et al. T-helper types 1, 2, 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 2004; 129: 267-72.
56. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, bipolar mania: Effects of psychotropic drugs. Mol Psychiatry 2002; 7: 1107-14.
57. Legros S, Mendlewicz J, Wybran J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. Eur Arch Psychiatry Neurol Sci 1985; 235: 9-11.
58. Li Z, Zhang C, Fan J, Yuan C, Huang J, Chen J, et al. Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. Br J Psychiatry 2014; 205: 29-35.
59. Lin CC, Lee CT, Lo YT, Huang TL. Brain-derived neurotrophic factor protein and mRNA levels in patients with bipolar mania- A preliminary study. Biomed J 2016; 39: 272-6.
60. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol 2004; 150: 116-22.
61. Loch AA, Zanetti MV, de Sousa RT, Chaim TM, Serpa MH, Gattaz WF, et al. Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 2015; 56: 243-6.
62. Lotrich FE, Butters MA, Aizenstein H, Marron MM, Reynolds 3rd CF, Gildengers AG. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry 2014; 29: 635-44.
63. Machado-Vieira R, DietrichMO, Leke R, Cereser VH, Zanatto V, Kapczinski F, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007; 61: 142-4.
64. Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN. Changes in brainderived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry 2007; 41: 321-6.
65. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014; 47: 199-211.
66. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: Focus on acutely ill patients. J Affect Disord 2006; 90: 263-7.
67. Ortiz-Dominguez A, Hernandez ME, Berlanga C, Gutierrez-Mora D, Moreno J, Heinze G, et al. Immune variations in bipolar disorder: Phasic differences. Bipolar Disord 2007; 9: 596-602.
68. Panizzutti B, Gubert C, Schuh AL, Ferrari P, Bristot G, Fries GR, et al. Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker J Affect Disord 2015; 182: 64-9.
69. Rabie MA, Mohsen M, Ibrahim M, El-Sawy Mahmoud R. Serum level of brain derived neurotrophic factor (BDNF) among patients with bipolar disorder. J Affect Disord 2014; 162: 67-72.
70. Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM, Vieta E, et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med 2014; 44: 2409-18.
71. Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008; 107: 89-94.
72. Su SC, Sun MT, Wen MJ, Lin CJ, Chen YC, Hung YJ. Brain-derived neurotrophic factor, adiponectin, proinflammatory markers in various subtypes of depression in young men. Int J Psychiatry Med 2011; 42: 211-26.
73. Suwalska A, Sobieska M, Rybakowski JK. Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 2010; 62: 229-34.
74. Tramontina JF, Andreazza AC, Kauer-Sant'anna M, Stertz L, Goi J, Chiarani F, et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009; 452: 111-3.
75. Tsai SY, Chen KP, Yang YY, Chen CC, Lee JC, Singh VK, et al. Activation of indices of cell-mediated immunity in bipolarmania. Biol Psychiatry 1999; 45: 989-94.
76. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012; 136: 110-6.
77. Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord 2001; 64: 185-93.
78. Tunca Z, Ozerdem A, Ceylan D, Yalcin Y, Can G, Resmi H, et al. Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: The role of lithium. J Affect Disord 2014; 166: 193-200.
79. Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res 2015; 228: 386-92.
80. Versace A, Andreazza AC, Young LT, Fournier JC, Almeida JR, Stiffler RS, et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: Toward peripheral biomarkers of bipolar disorder. Mol Psychiatry 2014; 19: 200-8.
81. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Human psychopharmacology 2002; 17: 175-9.
82. Yanik M, Vural H, Tutkun H, Zoroglu SS, Savas HA, Herken H, et al. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 2004; 254: 43-7.
83. Breunis MN, Kupka RW, Nolen WA, Suppes T, Denicoff KD, Leverich GS, et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003; 53: 157-65.
84. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116: 214-7.
85. De Berardis D, Conti CM, Campanella D, Carano A, Scali M, Valchera A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol 2008; 21: 319-24.
86. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-v. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 447-58.
87. Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-in patients with bipolar disorder and schizophrenia: Differences in pro- A nd anti-inflammatory balance. Rev Bras Psiquiatr 2011; 33: 268-74.
88. Monteleone P, Serritella C, Martiadis V, Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008; 10: 95-100.
89. Walz JC, Magalhaes PV, Giglio LM, Cunha AB, Stertz L, Fries GR, et al. Increased serum neurotrophin-4/5 levels in bipolar disorder. J Psychiatr Res 2009; 43: 721-3.
90. Yatham LN, Kapczinski F, Andreazza AC, Trevor Young L, Lam RW, Kauer-Sant'anna M. Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 137-9.
91. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, antidepressant medications: Meta-analyses and implications. Biol Psychiatry. 2008; 64: 527-32.
92. Rybakowski JK. Response to lithium in bipolar disorder: Clinical and genetic findings. ACS Chem Neurosci 2014; 5: 413-21.
93. de Sousa RT, Zarate Jr CA, Zanetti MV, Costa AC, Talib LL, Gattaz WF, et al. Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatr Res 2014; 50: 36-41.
94. Kato TA, Monji A, Mizoguchi Y, Hashioka S, Horikawa H, Seki Y, et al. Anti-Inflammatory properties of antipsychotics via microglia modulations: Are antipsychotics a 'fire extinguisher' in the brain of schizophrenia Mini Rev Med Chem 2011; 11: 565-74.
95. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates, 1988.
96. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: Meta-analysis and implications. Mol Psychiatry 2015; 20: 1108-19.
97. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: Evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014; 19: 791-800.
98. Maes M. A review on the acute phase response in major depression. Rev Neurosci 1993; 4: 407-16.
99. Hodes GE, Menard C, Russo SJ. Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress 2016; 4: 15-22.
100. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A metaanalysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-57.
101. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M. Cumulative metaanalysis of interleukins 6 and 1beta, tumour necrosis factor alpha and Creactive protein in patients with major depressive disorder. Brain Behav Immunity 2015; 49: 206-15.
102. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-17.
103. Doganavsargil-Baysal O, Cinemre B, Aksoy UM, Akbas H, Metin O, Fettahoglu C, et al. Levels of TNF-alpha, soluble TNF receptors (sTNFR1, sTNFR2), cognition in bipolar disorder. Hum Psychopharmacol 2013; 28: 160-7.
104. Boll KM, Noto C, Bonifacio KL, Bortolasci CC, Gadelha A, Bressan RA, et al. Oxidative and nitrosative stress biomarkers in chronic schizophrenia. Psychiatry Res 2017; 253: 43-8.
105. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11: 851-76.
106. Baek D, Park Y. Association between erythrocyte n-3 polyunsaturated fatty acids and biomarkers of inflammation and oxidative stress in patients with and without depression. Prostaglandins Leukot Essent Fatty Acids 2013; 89: 291-6.
107. Spanemberg L, Caldieraro MA, Vares EA, Wollenhaupt-Aguiar B, Kauer-Sant'Anna M, Kawamoto SY, et al. Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure. Neuropsychiatr Dis Treat 2014; 10: 1523-31.
108. Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front Psychiatry 2014; 5: 98.
109. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407-18.
110. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403.
111. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rimm EB. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003; 11: 1055-64.
112. Kapczinski F, Simões Fernandes B, Kauer-Sant'Anna M, Gama CS, Yatham LN, Berk M. The concept of staging in bipolar disorder: The role of BDNF and TNFalpha as biomarkers. Acta Neuropsychiatrica 2009; 21: 272-4.
113. Sigitova E, Fisar Z, Hroudova J, Cikankova T, Raboch J. Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci 2017; 71: 77-103.
114. McIntyre RS, Soczynska JK, Cha DS, Woldeyohannes HO, Dale RS, Alsuwaidan MT, et al. The prevalence and illness characteristics of DSM-5-defined 'mixed feature specifier' in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. J Affect Disord 2015; 172: 259-64.
115. Miller S, Suppes T, Mintz J, Hellemann G, Frye MA, McElroy SL, et al. Mixed depression in bipolar disorder: Prevalence rate and clinical correlates during naturalistic follow-up in the Stanley Bipolar Network. Am J Psychiatry 2016; 173: 1015-23.
116. Carvalho AF, Kohler CA, Fernandes BS, Quevedo J, Miskowiak KW, Brunoni AR, et al. Bias in emerging biomarkers for bipolar disorder. Psychol Med 2016; 46: 2287-97.
117. Hayes JF, Khandaker GM, Anderson J, Mackay D, Zammit S, Lewis G, et al. Childhood interleukin-6, C-reactive protein and atopic disorders as risk factors for hypomanic symptoms in young adulthood: A longitudinal birth cohort study. Psychol Med 2017; 47: 23-33.